Materials and methods for improved intragastric balloon devices

Information

  • Patent Grant
  • 9579226
  • Patent Number
    9,579,226
  • Date Filed
    Friday, August 28, 2015
    9 years ago
  • Date Issued
    Tuesday, February 28, 2017
    7 years ago
Abstract
Disclosed is a balloon of an intragastric device, comprising, in combination: a core of a first material and having an inner surface and an outer surface; and a coating of a second material on at least one of the inner surface of the core and the outer surface of the core. Disclosed is a method, comprising, in combination: creating a core of a balloon by a core in a first material; dipping at least one of an inner surface of the core and an outer surface of the core in a second material, whereby a coating is formed on at least one of the inner surface of the core and the outer surface of the core. Also disclosed are products by processed disclosed herein. The first material may be of a more dimensional consistency than the second material, have a greater elasticity than the second material, or be primarily of polydimethylsiloxane. The second material may be of higher acid resistance than the first material, be less permeable than the first material, or be primarily of polydiphenylsiloxane.
Description
BACKGROUND

This disclosure relates to implantable, expandable gastric devices. In particular, this disclosure relates to improved structures of balloons and methods of producing the same.


Many conventional implantable gastric devices have a balloon filled with a biocompatible fluid. Such gastric devices are generally inserted into the stomach when the balloon is deflated and then inflated in vivo. The gastric devices are often left in the stomach for an extended period of time to treat severe obesity or other conditions. The gastric devices are eventually removed after completing the treatment or for other reasons by deflating the balloon, grasping the gastric device with an extraction tool, and extracting the gastric device via the esophagus and mouth. Conventional gastric devices are deflated by attempting to puncture the balloon and aspirate the biocompatible fluid through a needle.


One challenge of conventional devices is that the balloon are generally fairly large in a deflated state because of the limited elasticity and expansion of the materials that can withstand the harsh environment within the stomach rupture. Many existing balloons for intragastric devices are made from polydiphenylsiloxane (PDPS), which resists degradation by acids, fungal growth and other microbial growth, but it has limited expansion. As such, the cuffs of such a balloon must have a fairly large diameter so that the balloon can be removed from a mandrel during the manufacturing process.


Another challenge of conventional intragastric devices is the life span of the balloon. For example, fungi or other microbes can grow into the material of the balloon and effectively decrease the wall thickness. This can weaken the balloon wall to the point that it ruptures under the pressure of the fluid in the balloon.





BRIEF DESCRIPTION OF THE DRAWINGS

Several embodiments of the present technology will become more apparent with reference to the following description taken in conjunction with the accompanying drawings wherein like reference numerals denote like elements and in which:



FIG. 1 shows a perspective view of a balloon;



FIG. 2 shows a perspective view of an intragastric device;



FIG. 3 shows a side view of an intragastric device;



FIG. 4 shows a top view of an intragastric device;



FIG. 5 shows a sectional view of a balloon with a magnified view;



FIG. 6 shows a sectional view of a balloon with a magnified view; and



FIG. 7 shows a sectional view of a balloon with a magnified view.





DETAILED DESCRIPTION

Specific details of several embodiments of the present technology are described below with reference to an intragastric device with compound balloon. Although many of the embodiments are described below with respect to a dual balloon intragastric device, other types of devices with only one balloon or more than two balloons may be within the scope of the technology. Moreover, several other embodiments of the technology can have different configurations, components, or procedures than those described in this section. A person of ordinary skill in the art, therefore, will accordingly understand that the technology may have other embodiments with additional elements, or the technology may have other embodiments without several of the features shown and described below with reference to FIGS. 1-7.


Several embodiments of the technology are directed to a balloon of an intragastric device comprising, in combination, a substrate or core of a first material that has having an inner surface and an outer surface, and a coating of a second material on at least one of the inner or outer surfaces. The substrate, for example, can be more elastic and/or have more expansion than the coating, and the coating can be more resistant to fungal or other microbial growth than the substrate.


Additional embodiments of the technology are directed to a method comprising, in combination, forming a core or substrate of a first material into a balloon and covering at least one of an inner surface and/or outer surface of the substrate with a second material. The second material can be a coating that is sprayed, painted or applied by dipping the substrate into the second material, to form a smoother surface finish, as compared to a surface finish of a molded core, having a roughness from about 0.1 to 0.7 micron. This further inhibits or otherwise impedes the formation of biofilm (e.g., candida) on the coated surface of the balloon. Also disclosed are products by processed disclosed herein.


The first material may be of a more dimensionally stable or consistant than the second material and/or have a greater elasticity than the second material. In one embodiment, the first material comprises polydimethylsiloxane (PDMS). The second material may have a higher resistance to acid, be more resistant to fungal or other microbial activity, and be less permeable than the first material. In one embodiment, the second material comprises PDPS.


In the specific embodiment shown in FIG. 1, a balloon 30 can be one of several expandable, space filling components. In several embodiments, and as shown in FIG. 2, the balloon 30 may be a component of an intragastric device 10. For example, as further shown in FIG. 2, the intragastric device 10 can have a shaft 20 and a plurality of the balloons 30 may be joined or otherwise carried by the shaft 20.


The balloon 30 may have many different geometries and shapes according to the specific anatomy in which the balloon 30 is implanted. As shown in FIGS. 1 and 3, the balloon 30 may have at least one cuff 40 for interfacing with the shaft 20 (FIG. 2) such that the shaft 20 extends through the balloon 30. The balloon 30 may be an open or closed balloon, and the balloon 30 may have an inner surface and outer surface.


According to several embodiments of the technology, the intragastric device 10 may be configured for use as an implantable device within a gastric cavity. In many applications, the intragastric device 10 is implanted for several months in the stomach or other gastric cavity having high concentrations of acids and microbes that can deteriorate the balloon 30. The durability and longevity of the intragastric device 10 is accordingly defined, at least in part, by the ability of the balloon 30 to resist the harsh environment within the stomach. As such, the materials and manufacturing methods of the materials are key contributors as to balloon integrity and longevity.


According to embodiments, the balloon 30 may comprise a combination of two different silicone-containing materials. Two examples of such materials are PDMS and PDPS. PDMS may be represented as [SiO(CH3)2]n or graphically as follows:




embedded image


PDPS may be represented as [SiO(C6H5)2]n or graphically as follows:




embedded image


According to several embodiments of the technology, at least one of PDMS and PDPS may form the substrate or core of at least a portion of the balloon 30. Other materials, structures, or compounds may be mixed or cross-linked with the based material.


According to several embodiments of the technology, a plasma etching or coating may be provided to at least a portion of the balloon 30. Plasma etching may involve a high-speed stream of glow discharge (plasma) of an appropriate gas mixture being shot (in pulses) at a sample. The plasma source can be either charged (ions) or neutral (atoms and radicals). During the process, the plasma will generate volatile etch products at room temperature from the chemical reactions between the elements of the material etched and the reactive species generated by the plasma. The atoms of the shot element embed themselves at or just below the surface of the target, thus modifying the physical properties of the balloon 30. Etching may facilitate better adherence between layers of the balloon 30.


According to several embodiments of the technology, various coatings (e.g., hydrophilic) may be applied to at least a portion of substrate or core of the balloon 30. For example, a hydrophilic coating may be provided where two surfaces of the balloon 30 resist flow of fluid there through.


The respective chemical structures of PDMS and PDPS have relatively disparate characteristics, which may be summarized as follows:
















Polydimethylsiloxane
Polydiphenylsiloxane


















Manufacturing method:
Molding, extrusion
Dipping


Curing:
Heat
Heat


Consistency:
More dimensional
Less dimensional



(moldable)
(dipping)


Elasticity:
Higher
Lower


Tensile Strength:
Lower
Higher


Acid resistance:
Acceptable
Increased


Permeability:
Higher
Lower










In various applications and based on different aspects, each of PDMS and PDPS may be seen as providing certain advantages and disadvantages.


According to several embodiments of the technology, the dimensional stability or consistency and elasticity of PDMS materials and PDMS blends enable the balloon 30 to be formed using molding and extrusion processes instead of a dipping process. In particular, molding processes include molding the PDMS material over a mandrel, and the higher elasticities of PDMS materials compared to PDPS materials reduce the stresses involved in removing the mandrel. For example, the balloon 30 may be formed using a mandrel that has a larger diameter at a central portion than at one or both ends (corresponding to cuffs 40). For example, the diameter at the middle of a mandrel may be up to 600% larger than at the end of the mandrel. The balloon 30 must sufficiently elastic to remove the mandrel through the cuff 40 without damaging the cuff 40.


According to several embodiments of the technology, the expansion ratio of the balloon 30 from an uninflated state (i.e., before and during implant) to an inflated state (i.e, after implant) may be significant. For example, the balloon 30 may have an outer diameter of about 1.9″ in an uninflated state and about 4″ in an inflated state (over 200% expansion). By further example, the balloon 30 may have a volume of about 80 cc in an uninflated state and about 450 cc in an inflated state (over 500% expansion). These factors are well-served by PDMS materials and PDMS blends. As such, PDMS and PDMS blends are well suited for the substrate or core of the balloon 30.


In accordance with several embodiments of the invention, the higher acid resistance and less permeability of PDPS materials and PDPS blends, compared to PDMS based materials, better limit the ingress or egress of materials across the walls of the balloon 30 and support longevity of the balloon 30. Generally, PDPS, as compared to PDMS, is less able to provide consistent wall thicknesses and is less capable of generating molding friendly features, but more capable of resisting acids and growth of fungi or bacteria.


In several specific embodiments of the technology, the balloon 30 has a multiple-material composition in which a plurality of disparate materials and material blends may be provide in layers forming walls of the balloon 30. For example, a wall of the balloon 30 may have a substrate or core with at least one coating on an inner or outer surface thereof.



FIGS. 5 and 6 illustrate specific embodiments of the technology. In the embodiment shown in FIG. 5, the balloon can have a substrate or core 50 and outer coating 60a over an outer surface of the core 50. The outer coating 60a may be provided, for example, by a dipping process after core 50 is formed. In the embodiment shown in FIG. 6, the balloon 30 can have in inner coating 60b over an inner surface of the core 50. The inner coating 60b may be provided, for example, by a dipping process after core 50 is formed and the balloon inverted inside-out.



FIG. 7 illustrates another embodiment in which the balloon has the substrate or core 50, the outer coating 60a over the outer surface of the core, and an inner coating 60b over the inner surface of the core 50. The outer coating 60a and inner coating 60b may be provided, for example, by a dipping process after core 50 is formed.


In selected embodiments, the substrate or core 50 can comprise PDMS or another material that is moldable and has a higher elasticity than PDPS. The inner and/or outer coatings 60a-b can comprises PDPS or another material that is less permeable and more acid resistant than PDMS. According to several embodiments, the balloon 30 having a layered, multiple-material composition may benefit from the advantaged of each material while mitigating or minimizing the detriments of each.


The present technology is also directed to methods of making the balloon 30 is disclosed. In one embodiment, the substrate or core 50 may be molded of the first material, such as a liquid silicone rubber (LSR) grade material (e.g., such as PDMS). Those skilled in the art will recognize various molding and extrusion processes that may facilitate formation of core 50. The molding process can include injecting PDMS or a PDMS blend into a mold such that the molded material surrounds a mandrel or other form. After curing, the core 50 is removed from the mold, mandrel, or other device, and then the second material may be coated onto the inner and/or outer surface of the core 50. For example, the core 50 may be dipped in the second material to form at least one of the outer coating 60a and/or the inner coating 60b. Other embodiments of the method, the core 50 may be coated using other techniques, such as spraying, painting, coating, washing, etc. The second material can be PDPS or another suitable low-permeable, acid and fungal resistant material.


The core 50 may compose a substantial portion of the total sum of the balloon 30 or at least the walls thereof. For example, the thickness of core 50 may be about 0.001 inch to about 1.0 inch. By further example, the thickness of core 50 may be about 0.024 inch to about 0.030 inch. The core 50 can have other thicknesses based on the needs and applications of the desired product.


The outer coating 60a or the inner coating 60b may be a thin relative to the thickness of core 50. For example, the outer coating 60a or the inner coating 60b may have a thickness of about 1% to about 99% of the thickness of core 50. By further example, the outer coating 60a or the inner coating 60b may have a thickness of about 10% to about 20% of the thickness of core 50. The inner and outer coating 60a-b can have other thicknesses based on the needs and applications of the desired product. It should be noted that outer coating 60a or inner coating 60b comprising PDPS materials increase the stiffness of the balloon 30 and reduce elongation properties thereof.


In still additional embodiments of the technology, the core 50 and/or the coating 60 can include anti-microbial or other additives to impart additional therapeutic, durability, or other properties to the balloon 30. For example, such additives can be distributed homogeneously in the coating 60, or the additives can be a constituent of another coating applied directly to the core 50 or to the coating 60. When such an additional coating is applied directly to the core 50, the coating 60 can be applied onto the other coating. In several specific examples, the additives can comprise salt or silver-based anti-microbial materials that inhibit the growth of microbes on and/or into the core 50.


The multi-layered construction of first and second materials of several embodiments of the balloon may have a substantially consistent surface and retain elastic material properties, increased acid resistance, and lower permeability. For example, the first material of the core 50 can provide good elasticity enable molding processes that provide a controlled wall thickness, and the second material of the coating 60 can provide good resistance to acid, fungus, bacteria and other microbes. The second material of the coating 60 can also have a low permeability.


Although the method and agent have been described in terms of what are presently considered to be the most practical and preferred embodiments, it is to be understood that the disclosure need not be limited to the disclosed embodiments. It is intended to cover various modifications and similar arrangements included within the spirit and scope of the claims, the scope of which should be accorded the broadest interpretation so as to encompass all such modifications and similar structures. The present disclosure includes any and all embodiments of the following claims.


It should also be understood that a variety of changes may be made without departing from the essence of the invention. Such changes are also implicitly included in the description. They still fall within the scope of this invention. It should be understood that this disclosure is intended to yield a patent covering numerous aspects of the invention both independently and as an overall system and in both method and apparatus modes.


Further, each of the various elements of the invention and claims may also be achieved in a variety of manners. This disclosure should be understood to encompass each such variation, be it a variation of an embodiment of any apparatus embodiment, a method or process embodiment, or even merely a variation of any element of these.


Particularly, it should be understood that as the disclosure relates to elements of the invention, the words for each element may be expressed by equivalent apparatus terms or method terms—even if only the function or result is the same.


Such equivalent, broader, or even more generic terms should be considered to be encompassed in the description of each element or action. Such terms can be substituted where desired to make explicit the implicitly broad coverage to which this invention is entitled.


It should be understood that all actions may be expressed as a means for taking that action or as an element which causes that action.


Similarly, each physical element disclosed should be understood to encompass a disclosure of the action which that physical element facilitates.


Any patents, publications, or other references mentioned in this application for patent are hereby incorporated by reference. In addition, as to each term used it should be understood that unless its utilization in this application is inconsistent with such interpretation, common dictionary definitions should be understood as incorporated for each term and all definitions, alternative terms, and synonyms such as contained in at least one of a standard technical dictionary recognized by artisans and the Random House Webster's Unabridged Dictionary, latest edition are hereby incorporated by reference.


Finally, all referenced listed in the Information Disclosure Statement or other information statement filed with the application are hereby appended and hereby incorporated by reference; however, as to each of the above, to the extent that such information or statements incorporated by reference might be considered inconsistent with the patenting of this/these invention(s), such statements are expressly not to be considered as made by the applicant(s).


In this regard it should be understood that for practical reasons and so as to avoid adding potentially hundreds of claims, the applicant has presented claims with initial dependencies only.


Support should be understood to exist to the degree required under new matter laws—including but not limited to United States Patent Law 35 USC 132 or other such laws—to permit the addition of any of the various dependencies or other elements presented under one independent claim or concept as dependencies or elements under any other independent claim or concept.


To the extent that insubstantial substitutes are made, to the extent that the applicant did not in fact draft any claim so as to literally encompass any particular embodiment, and to the extent otherwise applicable, the applicant should not be understood to have in any way intended to or actually relinquished such coverage as the applicant simply may not have been able to anticipate all eventualities; one skilled in the art, should not be reasonably expected to have drafted a claim that would have literally encompassed such alternative embodiments.


Further, the use of the transitional phrase “comprising” is used to maintain the “open-end” claims herein, according to traditional claim interpretation. Thus, unless the context requires otherwise, it should be understood that the term “compromise” or variations such as “comprises” or “comprising”, are intended to imply the inclusion of a stated element or step or group of elements or steps but not the exclusion of any other element or step or group of elements or steps.


Such terms should be interpreted in their most expansive forms so as to afford the applicant the broadest coverage legally permissible.

Claims
  • 1. A method, comprising, in combination: creating a core of a balloon by molding a core of a first material; andcoating an inner surface of the core and optionally an outer surface of the core with a second material, wherein the first material has a different elasticity than the second material, and wherein coating further comprises: at least one of spraying, painting, and dipping the inner surface and optionally the outer surface to form a smooth surface finish having a roughness from approximately 0.1 microns to approximately 0.7 micron.
  • 2. The method of claim 1, further comprising fixing the balloon to a shaft of an intragastric device.
  • 3. The method of claim 1, wherein the first material is more dimensional stable than the second material.
  • 4. The method of claim 1, wherein the first material has a greater elasticity than the second material.
  • 5. The method of claim 1, wherein the first material is primarily of polydimethylsiloxane.
  • 6. The method of claim 5, wherein the second material has higher acid resistance than the first material.
  • 7. The method of claim 5, wherein the second material is less permeable than the first material.
  • 8. The method of claim 5, wherein the second material is primarily of polydiphenylsiloxane.
  • 9. A product by the process of claim 1.
  • 10. A method, comprising, in combination: creating a core of a balloon by molding a core of a first material; andcoating an inner surface of the core and optionally an outer surface of the core with a second material to form a smooth surface finish having a roughness of approximately 0.1-0.7 micron, wherein the first material has a different elasticity than the second material.
CROSS-REFERENCE TO RELATED APPLICATION

The present application is a divisional of U.S. application Ser. No. 13/577,618, filed Aug. 28, 2012, which is a national stage entry of PCT Application No. PCT/US2011/024082, filed Feb. 8, 2011, which claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 61/302,465, filed Feb. 8, 2010, the disclosures of which are incorporated herein by reference in their entireties. This application incorporates by reference: U.S. Pat. Pub. No. 2007/0100367, published May 3, 2007; U.S. Pat. Pub. No. 2007/0100368, published May 3, 2007; U.S. Pat. Pub. No. 2007/0100369, published May 3, 2007; U.S. Pat. Pub. No. 2007/0149994, published Jun. 28, 2007; U.S. Pat. Pub. No. 2008/0243071, published Oct. 2, 2008; U.S. Pat. Pub. No. 2008/0319471, published Dec. 25, 2008; U.S. Pat. Pub. No. 2005/0159769, published Jul. 21, 2005; U.S. Pat. Pub. No. 2009/0048624, published Feb. 19, 2009; WIPO Pub. No. WO 2007/053556, published Oct. 5, 2007; WIPO Pub. No. WO 2007/053707, published Oct. 5, 2007; WIPO Pub. No. WO 2007/053706, published Oct. 5, 2007; and WIPO Pub. No. WO 2007/075810, published May 7, 2007; each as if fully set forth herein in its entirety.

US Referenced Citations (211)
Number Name Date Kind
1666690 Drevitson Apr 1928 A
1690995 Pratt Nov 1928 A
2493326 Trinder Jan 1950 A
2579301 Buntin Dec 1951 A
3131867 Miller et al. May 1964 A
4133315 Berman et al. Jan 1979 A
4198983 Becker et al. Apr 1980 A
4246893 Berson Jan 1981 A
4356824 Vazquez Nov 1982 A
4368739 Nelson, Jr. Jan 1983 A
4416267 Garren et al. Nov 1983 A
4465072 Taheri Aug 1984 A
4465818 Shirahata et al. Aug 1984 A
4485805 Foster, Jr. Dec 1984 A
4543089 Moss Sep 1985 A
4598699 Garren et al. Jul 1986 A
4694827 Weiner et al. Sep 1987 A
4723547 Kullas et al. Feb 1988 A
4899747 Garren et al. Feb 1990 A
4940458 Cohn Jul 1990 A
5073347 Garren et al. Dec 1991 A
5084061 Gau et al. Jan 1992 A
5123840 Nates Jun 1992 A
5234454 Bangs Aug 1993 A
5259399 Brown Nov 1993 A
5263934 Haak Nov 1993 A
5273536 Savas Dec 1993 A
5318530 Nelson, Jr. Jun 1994 A
5334187 Fischell et al. Aug 1994 A
5431173 Chin et al. Jul 1995 A
5496271 Burton et al. Mar 1996 A
5516812 Chu et al. May 1996 A
5575772 Lennox Nov 1996 A
5639810 Smith, III et al. Jun 1997 A
5643209 Fugoso et al. Jul 1997 A
5730722 Wilk Mar 1998 A
5779728 Lunsford et al. Jul 1998 A
5857991 Grothoff et al. Jan 1999 A
5876376 Schwab et al. Mar 1999 A
5904701 Daneshvar May 1999 A
5938669 Klaiber et al. Aug 1999 A
5976073 Ouchi Nov 1999 A
5993473 Chan et al. Nov 1999 A
5997503 Willis et al. Dec 1999 A
6050274 Gelardi et al. Apr 2000 A
6149621 Makihara Nov 2000 A
6179878 Duerig et al. Jan 2001 B1
6254355 Gharib Jul 2001 B1
6276567 Diaz et al. Aug 2001 B1
6280411 Lennox Aug 2001 B1
6423058 Edwards et al. Jul 2002 B1
6427089 Knowlton Jul 2002 B1
6454785 De Hoyos Garza Sep 2002 B2
6524234 Ouchi Feb 2003 B2
6535764 Imran et al. Mar 2003 B2
6540789 Silverman et al. Apr 2003 B1
6547788 Maguire et al. Apr 2003 B1
6579301 Bales et al. Jun 2003 B1
6592552 Schmidt Jul 2003 B1
6613018 Bagga et al. Sep 2003 B2
6613037 Khosravi et al. Sep 2003 B2
6689051 Nakada Feb 2004 B2
6706010 Miki et al. Mar 2004 B1
6746460 Gannoe et al. Jun 2004 B2
6826428 Chen et al. Nov 2004 B1
6850128 Park Feb 2005 B2
6866657 Shchervinsky Mar 2005 B2
6869431 Maguire et al. Mar 2005 B2
6890300 Lloyd et al. May 2005 B2
6890346 Ganz et al. May 2005 B2
6902535 Eberhart et al. Jun 2005 B2
6923754 Lubock Aug 2005 B2
6931286 Sigg et al. Aug 2005 B2
6939299 Petersen et al. Sep 2005 B1
6942680 Grayzel et al. Sep 2005 B2
6958052 Charlton Oct 2005 B1
6981980 Sampson et al. Jan 2006 B2
7001419 DiCaprio et al. Feb 2006 B2
7016735 Imran et al. Mar 2006 B2
7020531 Colliou et al. Mar 2006 B1
7033373 de la Torre et al. Apr 2006 B2
7056305 Garza Alvarez Jun 2006 B2
7076305 Imran et al. Jul 2006 B2
7081125 Edwards et al. Jul 2006 B2
7131945 Fink et al. Nov 2006 B2
7483746 Lee et al. Jan 2009 B2
7625355 Yu Dec 2009 B2
7749254 Sobelman et al. Jul 2010 B2
7828749 Douglas et al. Nov 2010 B2
7829572 Didiuk et al. Nov 2010 B2
7931693 Binmoeller Apr 2011 B2
8083757 Gannoe et al. Dec 2011 B2
8142469 Sosnowski et al. Mar 2012 B2
8226602 Quijana et al. Jul 2012 B2
8556925 Makower et al. Oct 2013 B2
8683881 Bouasaysy et al. Apr 2014 B2
8840952 Ashby et al. Sep 2014 B2
8845672 Alverdy Sep 2014 B2
8894568 Kwok et al. Nov 2014 B2
9050174 Pecor et al. Jun 2015 B2
20010022988 Schwarz et al. Sep 2001 A1
20010037127 De Hoyos Garza Nov 2001 A1
20020055757 Torre et al. May 2002 A1
20020107515 Edwards et al. Aug 2002 A1
20020161388 Samuels et al. Oct 2002 A1
20020173804 Rousseau Nov 2002 A1
20030105800 Cullen Jun 2003 A1
20030114878 Diederich et al. Jun 2003 A1
20030171768 McGhan Sep 2003 A1
20030187390 Bates et al. Oct 2003 A1
20040044354 Gannoe et al. Mar 2004 A1
20040059289 Garza Alvarez Mar 2004 A1
20040059290 Palasis Mar 2004 A1
20040073162 Bleam et al. Apr 2004 A1
20040087902 Richter May 2004 A1
20040093058 Cottone et al. May 2004 A1
20040106899 McMichael et al. Jun 2004 A1
20040116897 Aboul- Hosn Jun 2004 A1
20040127915 Fleenor et al. Jul 2004 A1
20040220665 Hossainy et al. Nov 2004 A1
20040236280 Rice et al. Nov 2004 A1
20040236361 Sakurai Nov 2004 A1
20040254600 Zarbatany et al. Dec 2004 A1
20050027283 Richard et al. Feb 2005 A1
20050027313 Shaker Feb 2005 A1
20050038415 Rohr et al. Feb 2005 A1
20050055039 Burnett et al. Mar 2005 A1
20050059990 Ayala et al. Mar 2005 A1
20050075624 Miesel Apr 2005 A1
20050085792 Gershowitz Apr 2005 A1
20050119674 Gingras Jun 2005 A1
20050131442 Yachia et al. Jun 2005 A1
20050143784 Imran Jun 2005 A1
20050159769 Alverdy Jul 2005 A1
20050177103 Hunter et al. Aug 2005 A1
20050192615 Torre et al. Sep 2005 A1
20050228504 Demarais Oct 2005 A1
20050267595 Chen et al. Dec 2005 A1
20050267596 Chen et al. Dec 2005 A1
20050273060 Levy et al. Dec 2005 A1
20060058829 Sampson et al. Mar 2006 A1
20060142700 Sobelman et al. Jun 2006 A1
20060178691 Binmoeller Aug 2006 A1
20060184112 Horn et al. Aug 2006 A1
20060259020 Sharratt Nov 2006 A1
20070016262 Gross et al. Jan 2007 A1
20070078476 Hull et al. Apr 2007 A1
20070083224 Hively Apr 2007 A1
20070100367 Quijano et al. May 2007 A1
20070100368 Quijano et al. May 2007 A1
20070100369 Cragg et al. May 2007 A1
20070118168 Lointier et al. May 2007 A1
20070135829 Paganon Jun 2007 A1
20070142770 Rioux et al. Jun 2007 A1
20070149994 Sosnowski et al. Jun 2007 A1
20070173881 Birk et al. Jul 2007 A1
20070233161 Weller et al. Oct 2007 A1
20070250020 Kim et al. Oct 2007 A1
20070265369 Muratoglu et al. Nov 2007 A1
20070265598 Karasik Nov 2007 A1
20070288033 Murature et al. Dec 2007 A1
20080058887 Griffin et al. Mar 2008 A1
20080082056 Mauch et al. Apr 2008 A1
20080085887 Didiuk et al. Apr 2008 A1
20080097513 Kaji et al. Apr 2008 A1
20080119729 Copa et al. May 2008 A1
20080172079 Birk Jul 2008 A1
20080190363 Chen et al. Aug 2008 A1
20080208135 Annunziata Aug 2008 A1
20080208241 Weiner et al. Aug 2008 A1
20080233167 Li Sep 2008 A1
20080243071 Quijano et al. Oct 2008 A1
20080243166 Paganon et al. Oct 2008 A1
20080255601 Birk Oct 2008 A1
20080312679 Hardert et al. Dec 2008 A1
20080319471 Sosnowski et al. Dec 2008 A1
20090048624 Alverdy Feb 2009 A1
20090259236 Burnett et al. Oct 2009 A2
20090275973 Chen et al. Nov 2009 A1
20090287231 Brooks et al. Nov 2009 A1
20100023047 Simpson Jan 2010 A1
20100049224 Vargas Feb 2010 A1
20100057197 Weber Mar 2010 A1
20100063530 Valencon et al. Mar 2010 A1
20100130998 Alverdy May 2010 A1
20100174307 Birk et al. Jul 2010 A1
20100191270 Garza et al. Jul 2010 A1
20100234853 Pecor et al. Sep 2010 A1
20100243135 Pepper et al. Sep 2010 A1
20100251837 Bouasaysy et al. Oct 2010 A1
20110172767 Rathi et al. Jul 2011 A1
20110178544 Sosnowski et al. Jul 2011 A1
20110276076 Paganon Nov 2011 A1
20110295300 Verd et al. Dec 2011 A1
20120191126 Pecor et al. Jul 2012 A1
20120271336 Hamman et al. Oct 2012 A1
20120271338 Bouasaysy et al. Oct 2012 A1
20120289992 Quijano et al. Nov 2012 A1
20130035710 Bouasaysy et al. Feb 2013 A1
20130053880 Bouasaysy et al. Feb 2013 A1
20130060274 Bouasaysy Mar 2013 A1
20130102876 Limon et al. Apr 2013 A1
20130261654 Bouasaysy et al. Oct 2013 A1
20130296914 Quijano et al. Nov 2013 A1
20140031850 Bouasaysy et al. Jan 2014 A1
20140257358 Alverdy Sep 2014 A1
20140371775 Ashby et al. Dec 2014 A1
20150216529 Kwok et al. Aug 2015 A1
20150238342 Sosnowski et al. Aug 2015 A1
20150265811 Pecor Sep 2015 A1
20160008156 Pecor et al. Jan 2016 A1
Foreign Referenced Citations (49)
Number Date Country
2638988 May 2007 CA
8708978 Nov 1987 DE
0103481 Mar 1984 EP
0457456 Nov 1991 EP
0485903 May 1992 EP
1781183 May 2007 EP
2862525 May 2005 FR
2892297 Apr 2007 FR
2090747 Jul 1982 GB
2139902 Nov 1984 GB
S57168674 Oct 1982 JP
S6415063 Jan 1989 JP
01091872 Apr 1989 JP
H08322943 Dec 1996 JP
2001128985 May 2001 JP
2006333888 Dec 2006 JP
2015154964 Aug 2015 JP
2016127954 Jul 2016 JP
8805671 Aug 1988 WO
WO-9000369 Jan 1990 WO
WO-9925418 May 1999 WO
WO-0141700 Jun 2001 WO
WO-0166166 Sep 2001 WO
WO-0240081 May 2002 WO
2005082296 Sep 2005 WO
2005107641 Nov 2005 WO
2005120363 Dec 2005 WO
WO-2006035446 Apr 2006 WO
WO-2006056944 Jun 2006 WO
WO-2006128978 Dec 2006 WO
WO-2007027812 Mar 2007 WO
WO-2007053556 May 2007 WO
WO-2007053706 May 2007 WO
WO-2007053707 May 2007 WO
WO-2007075810 Jul 2007 WO
WO-2008042819 Apr 2008 WO
WO-2008121831 Oct 2008 WO
WO-2009055386 Apr 2009 WO
WO-2009112786 Sep 2009 WO
WO-2010048021 Apr 2010 WO
WO-2010115161 Oct 2010 WO
WO-2011011629 Jan 2011 WO
WO-2011011741 Jan 2011 WO
WO-2011011743 Jan 2011 WO
WO-2011024077 Mar 2011 WO
WO-2011038270 Mar 2011 WO
WO-2011097637 Aug 2011 WO
WO-2011127205 Oct 2011 WO
WO-2012048226 Apr 2012 WO
Non-Patent Literature Citations (70)
Entry
Canadian 2nd Office Action Application No. CA 2680124, Applicant: Reshape Medical, Inc., mailed Jul. 9, 2015, 3 pages.
European Examination Report; Application No. EP06827313.5, Applicant: Reshape Medical Inc., mailed Jul. 13, 2015, 4 pages.
European Examination Report; Application No. EP06847847.8, Applicant: Reshape Medical Inc., mailed Jul. 13, 2015, 4 pages.
Cronin, Carmel G. et al., “Normal small bowel wall characteristics on MR enterography,” European Journal of Radiology 74(2):207-211, Aug. 2010.
Gray, Henry, Anatomy of the Human Body. Philadelphia: Lea & Febiger, 1918. Section XI Splanchnology, 2g. The Small Intestine. Bartleby.com, 2000. Web. URL: www.bartleby.com/107/248.html. Accessed: Oct. 26, 2015. 12 pages.
Partial Supplementary European Search Report for European Application No. 11740535.7, Applicant: ReShape Medical, Inc., mailed Oct. 20, 2015, 7 pages.
Final Office Action for Japanese Application No. 2014-52972, Applicant: ReShape Medical, Inc., mailed on Oct. 9, 2015, 8 pages.
“Living with the BIB: BioEnterics Intragastric Balloon Program: Patient Information”; INAMED Health: Bioenterics Corporation, ECO-SBA-10434; dated Apr. 20, 2004 and May 14, 2005, located online at: www.sydneyobesity.com.au/pdf/M946-01.pdf; 10 pages.
Canadian 2nd Office Action Application No. CA 2484838, Applicant: ReShape Medical, Inc., mailed Sep. 24, 2010, 3 pages.
Canadian Office Action: Application No. CA 2680124, Applicant: ReShape Medical Corporation, mailed Nov. 4, 2014, 3 pages.
Canadian Office Action; Application No. CA 2484838, Applicant: ReShape Medical, Inc., mailed Nov. 13, 2009, 3 pages.
Canadian Office Action; Application No. CA 2638163, Applicant: ReShape Medical Corporation, mailed Jul. 17, 2013, 2 pages.
Canadian Office Action; Application No. CA 2638163, Applicant: ReShape Medical Corporation, mailed Mar. 10, 2015, 4 pages.
Canadian Office Action; Application No. CA 2638988, Applicant ReShape Medical Corporation, mailed Dec. 22, 2014 3 pages.
Canadian Office Action; Application No. CA 2638988, Applicant ReShape Medical Corporation, mailed Mar. 6, 2014, 4 pages.
Canadian Office Action; Application No. CA 2638988, Applicant: ReShape Medical Corporation, mailed May 28, 2013, 3 pages.
Canadian Office Action; Application No. CA 2638989, Applicant: ReShape Medical Corporation, mailed May 22, 2013 3 pages.
Canadian Office Action; Application No. CA 2640554, Applicant: ReShape Medical Corporation, mailed May 27, 2013, 2 pages.
Canadian Office Action; Application No. CA 2691530, mailed Dec. 18, 2014, 4 pages.
Canadian Office Action; Application No. CA 2780085, Applicant: ReShape Medical, Inc., mailed Jul. 23, 2012, 2 pages.
European Examination Report; Application No. 03726447.0, Applicant: Applied Medical Resources Corporation: Oct. 26, 2007, 4 pages.
European Examination Report; Application No. EP 10802918.2, Applicant: ReShape Medical, Inc., mailed Dec. 17, 2014, 5 pages.
European Examination Report; Application No. EP108029943, Applicant: ReShape Medical, Inc., mailed Dec. 18, 2014, 4 pages.
European Examination Reported; Application No. 08771842.5, May 7, 2015, 5 pages.
European Search Report—Supplementary; EP 03726447.0, Applicant: Applied Medical Resources Corporation: Mar. 1, 2006, 3 pages.
European Supplementary Search Report; Application No. 08771842.5, Apr. 24, 2015, 3 pages.
European Supplementary Search Report; EP Application No. 10802918.2, Applicant: ReShape Medical, Inc., mailed Jun. 5, 2013, 6 pages.
European Supplementary Search Report; EP Application No. 10802994.3, Applicant: ReShape Medical, Inc., mailed Jun. 28, 2013, 8 pages.
Extended European Search Report; Application No. 08732989.2, Applicant: ReShape Medical, Inc., mailed Oct. 16, 2014, 7 pages.
Extended European Search Report; Application No. 11748141.6, Applicant: ReShape Medical Corporation, mailed Feb. 25, 2014, 6 pages.
Extended European Search Report; Application No. EP11740536.5, Applicant: ReShape Medical, Inc., mailed Jul. 3, 2014, 8 pages.
Extended European Search Report; Application No. EP11748141.6, Applicant: ReShape Medical, Inc., mailed Feb. 25, 2014, 6 pages.
Extended European Search Report; Application No. EP11766679.2, Applicant: ReShape Medical, Inc., mailed Dec. 12, 2013, 6 pages.
Extended European Search Report; Application No. EP11831683.5, Applicant: ReShape Medical, Inc., mailed Jul. 3, 2014, 8 pages.
Extended European Search Report; Application No. EP6827098.3, Applicant: ReShape Medical, Corporation, mailed on Aug. 25, 2014, 3 pages.
Extended European Search Report; Application No. EP6827313.5, Applicant: ReShape Medical Corporation, mailed Jul. 30, 2014, 5 pages.
Extended European Search Report; Application No. EP6827314.3, Applicant: ReShape Medical Corporation, mailed Aug. 1, 2014, 3 pages.
Extended European Search Report; application No. EP6847847.8, Applicant ReShape Medical Corporation, mailed Aug. 14, 2014, 5 pages.
International Search Report; International Application No. PCT/US11/55373, Applicant: ReShape Medical, Inc., dated: Jan. 20, 2012, 7 pages.
International Search Report; International Application No. PCT/US2010/042948; Applicant: ReShape Medical, Inc., Mailing Date Apr. 1, 2011, 11 pages.
International Search Report; International Application No. PCT/US2010/043134; Applicant: ReShape Medical, Inc., Mailing Date Apr. 27, 2011, 12 pages.
International Search Report; International Application No. PCT/US2010/043136; Applicant: ReShape Medical, Inc., Mailing Date Apr. 12, 2011, 9 pages.
International Search Report; International Application No. PCT/US2010/050260; Applicant: ReShape Medical, Inc., Mailing Date: Jun. 17, 2011, 9 pages.
International Search Report; International Application No. PCT/US2011/026233; Applicant: ReShape Medical, Inc., Mailing Date Apr. 26, 2011, 9 pages.
International Search Report; International Application No. PCT/US2011/031463; Applicant: ReShape Medical, Inc., Mailing Date: Jun. 27, 2011, 10 pages.
International Search Report; International Application No. PCT/US2003/012782, Applicant: Applied Medical Resources Corporation, dated: Oct. 28, 2003, 7 pages.
International Search Report; International Application No. PCT/US2006/042336, Applicant: Abdominus, Inc., dated: Mar. 14, 2007, 9 pages.
International Search Report; International Application No. PCT/US2006/042710, Applicant: Abdominus, Inc. et al., dated: Mar. 15, 2007, 9 pages.
International Search Report; International Application No. PCT/US2006/042711, Applicant: Abdominus, Inc. et al, dated: Mar. 16, 2007, 9 pages.
International Search Report; International Application No. PCT/US2006/048647, Applicant: Abdominus, Inc. et al., dated: May 22, 2007, 12 pages.
International Search Report; International Application No. PCT/US2008/058677, Applicant: ReShape Medical et al., dated: Aug. 21, 2008, 12 pages.
International Search Report; International Application No. PCT/US2008/068058, Applicant: ReShape Medical, Inc. et al, dated: Nov. 19, 2008, 11 pages.
International Search Report; International Application No. PCT/US2010/029865, Applicant: ReShape Medical, Inc., dated: Jan. 5, 2011, 9 pages.
International Search Report; International Application No. PCT/US2011/024077; Applicant: ReShape Medical, Inc., dated: Apr. 6, 2011, 12 pages.
International Search Report; International Application No. PCT/US2011/024082, Applicant: ReShape Medical, Inc., dated: Apr. 6, 2011, 10 pages.
Japanese Office Action; Application No. 2013-142327, mailed May 29, 2014, 4 pages.
Japanese Office Action; Application No. 2013-532976; mailed Jun. 26, 2015, 10 pages.
Japanese Office Action; Application No. 2014-52972, mailed Feb. 25, 2015, 7 pages.
Japanese Office Action; Application No. 2010-501261, mailed Sep. 7, 2012, 10 pages.
Japanese Office Action; Application No. 2010-515040, mailed Jan. 7, 2013, 17 pages.
Japanese Office Action; Application No. 2012-503759, mailed Mar. 24, 2014, 5 pages.
Japanese Office Action; Application No. 2013-43712, mailed Jan. 8, 2015, 8 pages.
Japanese Office Action; Application No. 2013-43712, mailed Nov. 15, 2013, 5 pages.
Japanese Office Action; Application No. 2013-043712, mailed Apr. 22, 2013, 5 pages.
Ostrovsky, ReShape Inflatable Gastric Balloon going on Trial as Weight Loss Option; http://www.medgadget.com/2010/02/ReShape—inflatable—gastric—balloon—system—going—on—trial—as—weight—loss—option.html Feb. 4, 2010, retrieved on Feb. 10, 2013.
ReShape Inflatable Gastric Balloon Going on Trial as Weight Loss Option, MedGadget: Internet Journal of Emerging Medical Technologies. Feb. 4, 2010, 5 pages.
Wahlen CH et al. “The BioEnterics Intragastric Balloon: How to use it” Obesity Surgery 2001; 11:524-527.
Chou, Chyuan et al., “Structural Effects on the Thermal Properties of PDPS/PDMS Copolymers,” Journal of Thermal Analysis, vol. 40, pp. 657-667, 1993.
European Search Report for European Application No. 11740535.7, Applicant: ReShape Medical, Inc., mailed Mar. 8, 2016, 14 pages.
Extended European Search Report; Application No. 15198773.2, Application ReShape Medical Corporation, mailed Jul. 15, 2016, 7 pages.
Related Publications (1)
Number Date Country
20150366691 A1 Dec 2015 US
Provisional Applications (1)
Number Date Country
61302465 Feb 2010 US
Divisions (1)
Number Date Country
Parent 13577618 US
Child 14839865 US